Clinical Trials on Gout and Asymptomatic Hyperuricemia in Portugal

Total 13 results

University of Lisbon
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.

Completed

The Immediate Effects of Spinal Manipulative Therapy on Kinetic and Kinematic Symmetry.

Asymptomatic Condition

Portugal
Novartis Pharmaceuticals

Completed

Long Term Study of Canakinumab (ACZ885) in Patients With Gout

Gouty Arthritis

Colombia, Spain, Taiwan, Russian Federation, Guatemala, Belgium, United States, Argentina, Czechia, Germany, Hungary, Poland, Portugal, Singapore, Slovakia, South Africa, Turkey, United Kingdom
Centro Hospitalar e Universitário de Coimbra, E...
University of Coimbra

Recruiting

Exocrine Pancreatic Insufficiency After Acute Pancreatitis and Pancreatic Enzyme Replacement Therapy

Immunology | Acute Pancreatitis | Exocrine Pancreatic Insufficiency | Gut Microbiota

Portugal
Mitralign, Inc.
CardioVascular Research Foundation, Korea; Regulatory and Clinical Research... and other collaborators

Unknown

Safety and Performance of the Trialign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS) (SCOUT-II)

Heart Valve Disease | Tricuspid Valve Insufficiency | Chronic Symptomatic Functional Tricuspid Regurgitation

Italy, Netherlands, Germany, Portugal
Juvantia Pharma Ltd
Santhera Pharmaceuticals

Unknown

Fipamezole in Neurogenic Orthostatic Hypotension (Foehn)

Parkinson's Disease | Multiple System Atrophy | Symptomatic Neurogenic Orthostatic Hypotension (NOH)

France, Portugal
P+F Products + Features GmbH
Meditrial USA Inc.

Recruiting

Pivotal Study of the Vienna Transcatheter Self Expandable Aortic Valve SE System (VIVA)

Symptomatic Aortic Stenosis

Spain, Argentina, Lithuania, Portugal, Brazil, Chile
Novartis Pharmaceuticals

Completed

A Study of the Efficacy of Canakinumab in Prevention of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy (Core Study) and a Long-term Study of the Efficacy and Safety of Canakinumab in Patients With Gout (Extension Study)

Gout

United States, Colombia, Russian Federation, Taiwan, Argentina, Turkey, Germany, Singapore, Spain, Hungary, Guatemala, Poland, South Africa, Slovakia, Portugal, Belgium, Czechia, United Kingdom
Cytokinetics

Enrolling by invitation

Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM (FOREST-HCM)

Symptomatic Hypertrophic Cardiomyopathy (HCM)

United States, France, Israel, Spain, United Kingdom, Italy, Portugal, Poland, Hungary, Denmark, Netherlands, Germany, Czechia
Medtronic Cardiovascular

Active, not recruiting

SMall Annuli Randomized To Evolut™ or SAPIEN™ Trial (SMART)

Aortic Valve Stenosis | Aortic Valve Replacement | Symptomatic Aortic Stenosis

United Kingdom, United States, Netherlands, Canada, Israel, Spain, Finland, Denmark, France, Germany, Switzerland, Italy, Portugal
Theravance Biopharma

Terminated

Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure (OAK)

Symptomatic Neurogenic Orthostatic Hypotension

United States, Spain, Portugal, United Kingdom, France, Denmark, Ukraine, Israel, Estonia, Poland, Italy, Russian Federation, Australia, Austria, Bulgaria, Canada, Germany, New Zealand
Theravance Biopharma

Completed

Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure (SEQUOIA)

Symptomatic Neurogenic Orthostatic Hypotension

United States, Spain, Israel, Hungary, Portugal, Australia, Canada, Germany, Russian Federation, Estonia, France, Italy, United Kingdom, Denmark, Poland, New Zealand, Austria, Bulgaria, Ukraine
Theravance Biopharma

Recruiting

Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy (CYPRESS)

MSA - Multiple System Atrophy | Symptomatic Neurogenic Orthostatic Hypotension

United States, Spain, United Kingdom, Hungary, Italy, Argentina, Austria, Poland, Germany, Portugal, Belgium, Brazil, Denmark, Canada, France, Chile, Estonia
Theravance Biopharma

Terminated

Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure (REDWOOD)

Parkinson's Disease (PD) | MSA | Symptomatic Neurogenic Orthostatic Hypotension | Pure Autonomic Failure (PAF)

United States, Spain, United Kingdom, Canada, France, Estonia, Australia, Israel, Denmark, Italy, Poland, New Zealand, Germany, Ukraine, Austria, Bulgaria, Portugal, Hungary, Russian Federation

Clinical Trials on Gout and Asymptomatic Hyperuricemia in Portugal

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in France

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations